CD Patients Immune Status Evaluation

Evaluating the Immune Status of Patients With Severe Crohn's Disease Using Single Cell Sequencing

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04135482

Enrollment

Registered

2019-10-22

Start date

2019-10-21

Completion date

2020-07-31

Last updated

2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Crohn's Diease

Keywords

singcel cell sequencing

Brief summary

Using single cell sequencing method to evaluate and compare the immune status of patients with severe CD.

Interventions

OTHERcolonic tissue biopsy

colonic tissue biospy of patients with severe crohn's disease using colonoscopy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1, Patients with severe CD（CDAI\>16,SES-CD\>19） 2, Patients have no previous any drug therapy targeting CD or just received treatment of 5-ASA -

Exclusion criteria

1, patients have previous treatment of prednisone, immunosuppressive agents such as azathioprine and biologic agents such as infliximab 2, patients were diagnozed as mild-moderate CD 3, patients have other immune disordered diseases such as SLE, PBC, AIH, PSC, sjogren syndrome, ulcerative colitis, and so on. \-

Design outcomes

Primary

Measure	Time frame	Description
single cell analysis of the colonic tissue of patients with severe crohn's disease	1 year	single cell analysis of the colonic tissue of patients with severe crohn's disease: inflammed and non-inflammed area from right colon or the terminal ileum

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026